As we know, the broad stock market indices have been resilient all year. And that strength, in large part, can be credited to a small group of stocks.
Among that group, the blue chip Internet stocks have led the way: Facebook, Amazon, Apple, Google and Netflix. Halfway through the year, those five stocks were up more than 40% on average. And those five stocks carry a lot of weight in the performance of the indexes.
And given the valuation of the index, you constantly hear how the market is overvalued or "fairly valued." It’s not true, for the reasons we’ve often discussed, related to historical low interest rates environments. And it’s certainly not true for the energy sector.
Take a look at energy performance year-to-date relative to the rest of the market:
Top Value Stocks To Watch For 2019: United Bankshares Inc.(UBSI)
- [By ]
In the Lightning Round, Cramer was bullish on Salesforce.com (CRM) , American Airlines (AAL) , Align Technology (ALGN) , Procter & Gamble (PG) , United Bankshares (UBSI) , Valeant Pharmaceuticals (VRX) and Dominion Energy (D) .
Top Value Stocks To Watch For 2019: Regeneron Pharmaceuticals, Inc.(REGN)
- [By Cory Renauer]
Attention bargain shoppers: There could be some deals in aisle biotech.Agenus Inc.(NASDAQ:AGEN)andRegeneron Pharmaceuticals (NASDAQ:REGN) dished out some disappointing losses in recent months, but the market’s reaction to recent events seems a bit overdone.
- [By Todd Campbell]
When a brand new class of cholesterol-lowering drugs called PCSK9 inhibitors won Food and Drug Administration (FDA) approval in 2015, it was heralded as the biggest advance in battling heart disease since the invention of statins. The launch of PCSK9 inhibitors was accompanied by billion-dollar-plus predictions for sales. However, revenue has fallen far shy of blockbuster status, leaving drugmakers Amgen Inc. (NASDAQ:AMGN), Regeneron Pharmaceuticals (NASDAQ:REGN), and Sanofi SA (NYSE:SNY) in the lurch.
- [By Johanna Bennett]
Shares of biotechnology giant Regeneron Pharmaceuticals (REGN) have climbed more than 4% today after Piper Jaffray analyst Ed Tenthoff upgraded the stock from a neutral to an overweight, with a $446 price target.
The upgrade comes just a few days after the drug maker released soft guidance for 2017 and forecasts called for slowing sales of the eye drug Eylea.
But Piper Jaffrays Tenthoff argues that anticipated approvals and deep pipeline should drive long-term value. Of particular importance: the atopic dermatitis drug Dupixent (dupilumab).
We are confident in FDA approval of Dupixent (dupilumab) in moderate-to-severe atopic dermatitis by the March 29th PDUFA date and in Europe in late 2017. The Phase III LIBERTY ASTHMA QUEST study has fully enrolled 1,858 persistent asthma patients to 200mg and 300mg subcu Dupixent q2W. We look for data this year to enable an sBLA submission by YE:17. Regeneron is conducting two Phase III trials in nasal polyps and will initiate Phase III pediatric atopic dermatitis and asthma trials. The company will report data from a Phase II eosinophilic esophagitis study in 1H:17 and begin a Phase II food allergy study in 2H:17. The FDA has deemed Sanofi’s Le Trait facility “acceptable”. As a result, we anticipate the partners will refile on Kevzara (sarilumab) and could gain approval in 2Q:17. These two launches should turn Regeneron’s antibody alliance with Sanofi profitable.
Todays news is the latest development in what has been a volatile time the drug maker. The shares have fallen sharply over the during the last three months, the result of a patent suit with Amgen (AMGN) over its anti-cholesterol drug Praluent, which a judge had set it wouldnt be able to sell in the U.S. , But last week, a judge granted a stay that would allow Regeneron to sell Praluent. It also fueled a pop in its shares.
The next day, however, Regeneron reported earnings, and while profits o
- [By ]
Celgene (CELG) : “I’d rather buy Amgen (AMGN) or Regeneron Pharmaceuticals (REGN) . I think Celgene overpaid for that acquisition a few years ago.”
- [By WWW.THESTREET.COM]
That’s why Cramer said he’ll be listening for news coming from Celgene (CEL) , Amgen (AMGN) , Allergan (AGN) , an Action Alerts PLUS holding, and Regenron (REGN) , all of which are set to present. Of the four, Cramer said he’s sticking with Allergan and Amgen.
- [By Chris Lange]
Shares of Amgen Inc. (NASDAQ: AMGN) saw a handy gain to close out the week after the company won a Delaware court ruling that blocked Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) from selling their cholesterol-lowering drug in the United States. Essentially the court found that the drug Praluent actually infringed upon Amgens patents for its rival treatment Repatha.
Top Value Stocks To Watch For 2019: Tandy Leather Factory, Inc.(TLF)
- [By Shane Hupp]
Tandy Leather Factory (NASDAQ: TLF) and Vera Bradley (NASDAQ:VRA) are both small-cap retail/wholesale companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
- [By Lee Jackson]
These companies also reported insider buying last week: Armour Residential REIT Inc. (NYSE: ARR), Ducommun Inc. (NYSE: DCO), PJT Partners Inc. (NYSE; PJT), Sonic Automotive Inc. (NYSE: SAH)and Tandy Leather Factory Inc. (NASDAQ: TLF).
Top Value Stocks To Watch For 2019: LifePoint Health, Inc.(LPNT)
- [By Lisa Levin] Companies Reporting Before The Bell
Celgene Corporation (NASDAQ: CELG) is projected to report quarterly earnings at $1.96 per share on revenue of $3.46 billion.
Aon plc (NYSE: AON) is expected to report quarterly earnings at $2.8 per share on revenue of $2.93 billion.
American Axle & Manufacturing Holdings, Inc. (NYSE: AXL) is estimated to report quarterly earnings at $0.81 per share on revenue of $1.75 billion.
Alibaba Group Holding Limited (NYSE: BABA) is expected to report quarterly earnings at $0.88 per share on revenue of $9.27 billion.
LifePoint Health, Inc. (NASDAQ: LPNT) is projected to report quarterly earnings at $1.13 per share on revenue of $1.62 billion.
V.F. Corporation (NYSE: VFC) is estimated to report quarterly earnings at $0.65 per share on revenue of $2.90 billion.
Newell Brands Inc. (NYSE: NWL) is expected to report quarterly earnings at $0.26 per share on revenue of $3.05 billion.
Titan International, Inc. (NYSE: TWI) is projected to report quarterly earnings at $0.04 per share on revenue of $407.27 million.
Boise Cascade Company (NYSE: BCC) is expected to report quarterly earnings at $0.45 per share on revenue of $1.09 billion.
Cheniere Energy, Inc. (NYSE: LNG) is estimated to report quarterly earnings at $0.39 per share on revenue of $1.59 billion.
Cboe Global Markets, Inc. (NASDAQ: CBOE) is projected to report quarterly earnings at $1.24 per share on revenue of $308.05 million.
ITT Inc. (NYSE: ITT) is estimated to report quarterly earnings at $0.73 per share on revenue of $683.96 million.
Fred's, Inc. (NASDAQ: FRED) is expected to report quarterly loss at $0.19 per share on revenue of $551.00 million.
Virtu Financial, Inc. (NASDAQ: VIRT) is projected to report quarterly earnings at $0.52 per share on revenue of $288.31 million.
Cheniere Energy Partners, L.P. (NYSE: CQP) is expected to report quarterly earnings at $0.57 per share on revenue of $1.38 billion.
Genesis Energy, L.P
Top Value Stocks To Watch For 2019: B Communications Ltd.(BCOM)
- [By Lisa Levin]
In trading on Monday, telecommunications services shares rose by just 0.2 percent. Meanwhile, top losers in the sector included B Communications Ltd (NASDAQ: BCOM), down 4 percent, and Partner Communications Company Ltd (ADR) (NASDAQ: PTNR), down 2 percent.
- [By Lisa Levin]
Monday afternoon, the telecommunication services shares climbed 0.69 percent. Meanwhile, top gainers in the sector included B Communications Ltd (NASDAQ: BCOM), up 5 percent, and China Unicom (Hong Kong) Limited (NYSE: CHU), up 3 percent.
- [By Lisa Levin]
In trading on Monday, telecommunications services shares fell by 0.77 percent. Meanwhile, top losers in the sector included United States Cellular Corp (NYSE: USM), down 5 percent, and B Communications Ltd (NASDAQ: BCOM), down 5 percent.
Top Value Stocks To Watch For 2019: EV Energy Partners, L.P.(EVEP)
- [By William Romov]
Before we show you our pick, here are the top 10 penny stocks to watch this week
Penny Stock Current Share Price Nov. 27-Dec. 1 Gain (as of Dec. 1)
Pyxis Tankers Inc. (Nasdaq: PXS) $4.10 122.83%
Ohr Pharmaceuticals Inc. (Nasdaq: OHRP) $1.28 68.42%
Cerecor Inc. (Nasdaq: CERC) $1.74 47.46%
Proteostasis Therapeutics Inc. (Nasdaq: PTI) $2.52 37.71%
UT Starcom Holdings Corp. (Nasdaq: UTSI) $5.20 37.20%
WMIH Corp. (Nasdaq: WMIH) $0.96 33.46%
PhaseRx Inc. (Nasdaq: PZRX) $0.90 30.29%
Bellerophon Therapeutics Inc. (Nasdaq: BLPH) $2.04 29.94%
EV Energy Partners LP (Nasdaq: EVEP) $0.86 27.76%
Catalyst Pharmaceuticals Inc. (Nasdaq: CPRX) $4.40 25.71%
FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, its completely free
- [By Money Morning Staff Reports]
But before we show you our pick, here are the top 10 penny stocks to watch this week…
Penny Stocks Current Share Price (as of Jan. 5) Jan. 2-5 Gain (as of Jan. 5)
My Size Inc. (Nasdaq: MYSZ) $1.66 152.28%
Cytori Therapeutics Inc. (Nasdaq: CYTX) $0.47 89.52%
DelMar Pharmaceuticals Inc. (Nasdaq: DMPI) $1.675 58.02%
CAS Medical Systems Inc. (Nasdaq: CASM) $1.09 55.71%
China HGS Real Estate Inc. (Nasdaq: HGSH) $1.83 47.58%
Aethlon Medical Inc. (Nasdaq: AEMD) $1.56 43.12%
Midatech Pharma Plc. (Nasdaq: MTP) $1.23 43.01%
Comstock Holding Cos. Inc. (Nasdaq: CHCI) $1.87 36.5%
Cenveo Inc. (Nasdaq: CVO) $1.20 31.82%
EV Energy Partners LP (Nasdaq: EVEP) $0.6844 31.62%
FREE PROFIT ALERTS: Get real-time recommendations on the best penny stock opportunities the moment we release them. Just sign up here, it’s completely free…